Newscope Capital Corporation
CSE: PHRM
Company Overview
Newscope Capital Corporation (CSE: PHRM), doing business through its wholly-owned subisidiary, Pharmather Inc., is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals.
The company repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Its team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets.
The company's goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and our clinical product pipeline with ketamine and psilocybin in the treatment of Parkinson’s Disease, depression, traumatic brain injury and stroke.
The company repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Its team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets.
The company's goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and our clinical product pipeline with ketamine and psilocybin in the treatment of Parkinson’s Disease, depression, traumatic brain injury and stroke.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
$0.00
Diluted EPS (ttm)
Management Team
Mr. Fabio Chianelli
CEO & Chairman
Mr. Carmelo Marrelli CPA, B.Comm., CA, CGA, ACIS
Chief Financial Officer
Andrew Todd
Corp. Sec.
Key Highlights
Market Capitalization
$11,826,638
Shares Outstanding
69,609,865
Shares Short (% of Float)
13,500 (0%)
Insider Ownership
23%